Aromatase Inhibitors (AIs) Versus Not (Placebo/Observation) as Late Extended Adjuvant Therapy for Postmenopausal Women with Early Stage Breast Cancer (BC): Overviews of Randomized Trials of AIs after similar to 5 Years of Tamoxifen
Հիմնական հեղինակներ: | Goss, P, Mamounas, E, Jakesz, R, Markopoulos, C, Dowsett, M, Peto, R, Godwin, J, Davies, C |
---|---|
Ձևաչափ: | Conference item |
Հրապարակվել է: |
2009
|
Նմանատիպ նյութեր
-
Meta-analysis of breast cancer outcomes in adjuvant trials of aromatase inhibitors versus tamoxifen
: Dowsett, M, և այլն
Հրապարակվել է: (2009) -
Variation in use of adjuvant tamoxifen.
: Davies, C, և այլն
Հրապարակվել է: (1998) -
Cost-effectiveness of Tamoxifen, Aromatase Inhibitor, and Switch Therapy (Adjuvant Endocrine Therapy) for Breast Cancer in Hormone Receptor Positive Postmenopausal Women in India
: Butani D, և այլն
Հրապարակվել է: (2021-11-01) -
Adjuvant chemotherapy plus tamoxifen compared with tamoxifen alone for postmenopausal breast cancer: meta-analysis of quality-adjusted survival.
: Gelber, R, և այլն
Հրապարակվել է: (1996) -
Aromatase inhibitors versus tarnoxifen as adjuvant therapy for postmenopausal women with estrogen receptor positive breast cancer: meta-analyses of randomized trials of monotherapy and switching strategies
: Ingle, J, և այլն
Հրապարակվել է: (2009)